We are using cookies to implement functions like login, shopping cart or language selection for this website. Furthermore we use Google Analytics to create anonymized statistical reports of the usage which creates Cookies too. You will find more information in our privacy policy.
OK, I agree I do not want Google Analytics-Cookies
Quintessence International



Forgotten password?


Quintessence Int 45 (2014), No. 9     20. Aug. 2014
Quintessence Int 45 (2014), No. 9  (20.08.2014)

Page 769-777, doi:10.3290/j.qi.a32243, PubMed:25019117

Risk of developing BRONJ among patients exposed to intravenous bisphosphonates following tooth extraction
Sanchis, Jose María / Bagán, Jose Vicente / Murillo, Judith / Díaz, Jose María / Asensio, Lucía
Objective: A study was designed to measure of the incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following tooth extraction in patients receiving or who have received intravenous bisphosphonates (Zometa, zoledronic acid).
Method and Materials: A prospective cohort study was made of 36 patients subjected to 62 tooth extractions. All these 36 patients had been treated or were receiving treatment with zoledronic acid.
Results: The incidence of BRONJ following 62 tooth extractions in patients treated with zoledronic acid 4 months after extraction was 14.5%.
Conclusion: No statistically significant associations were found with patient age, sex, hygiene index, total treatment time, surgical difficulty, or extraction site. However, the factors that significantly influenced the final presence of osteonecrosis were related to tooth extractions in the absence of periodontal disease, and if sockets remained unhealed at the month of extraction.

Keywords: bisphosphonates, BRONJ, osteonecrosis, zolendronic acid, Zometa